Bile duct cancer market seen reaching $9.47B by 2035

Market Research Future projects the global bile duct cancer market will nearly double from $4.70 billion in 2026 to $9.47 billion by 2035, driven by rising cholangiocarcinoma incidence, targeted therapy approvals and broader genomic testing. The forecast points to a faster shift from chemotherapy-heavy care toward precision oncology across hospitals, specialty clinics and major regional markets. Why it matters: - The bile duct cancer market is moving from a chemotherapy-led niche into a broader precision oncology category. - Market Research Future expects that shift to lift global revenue to $9.47 billion by 2035, up from $4.70 billion in 2026. - The change matters because more patients are being identified, tested and matched to targeted treatment options. What happened: - Market Research Future projected the global bile duct cancer market will grow at an 8.1% CAGR from 2026 to 2035. - The market base was estimated at $4.35 billion in 2025. - The report said the forecast is driven by rising cholangiocarcinoma incidence, expanding targeted and immunotherapy use, and broader precision diagnostics. - The company also made the report and customization requests available through sample access and customization links. The details: - Global cholangiocarcinoma incidence has risen about 140% over the past three decades, with intrahepatic disease increasing the fastest. - The American Cancer Society’s 2025 data estimates about 8,000 new bile duct cancer diagnoses a year in the U.S. - Southeast Asian countries including Thailand, Laos and Cambodia report age-standardized rates above 80 per 100,000, linked to endemic liver fluke infections. - More than 70% of patients present with unresectable or metastatic disease, which expands demand for systemic therapy. - National cancer registries in India and Brazil are capturing more cases as screening programs mature. - Gemcitabine-cisplatin remains the backbone regimen, but FGFR inhibitors, IDH1 inhibitors and immune checkpoint combinations are taking a larger role. - The FDA’s accelerated approvals of futibatinib and pemigatinib helped establish a faster regulatory path for mutation-targeted bile duct cancer drugs. - AstraZeneca’s TOPAZ-1 trial established durvalumab plus gemcitabine-cisplatin as a first-line standard for advanced biliary tract cancer. - The FDA granted Breakthrough Therapy Designation to an investigational KRAS G12C inhibitor for bile duct tumor drug development. - ESMO updated its biliary tract cancer guidance to recommend comprehensive genomic profiling for all newly diagnosed cholangiocarcinoma patients. - CMS finalized coverage for tumor-agnostic next-generation sequencing in 2023. - The UK NHS Genomic Medicine Service is rolling out whole-genome sequencing for all cancer patients. - Germany’s network of 17 designated Comprehensive Cancer Centers supports multidisciplinary hepatic duct cancer care. Between the lines: - The report suggests bile duct cancer is becoming a testing ground for precision oncology reimbursement, diagnostics and drug access. - Coverage decisions for genomic profiling are likely to matter as much as drug approvals because they determine who gets matched to targeted therapy. - The market remains fragmented, but molecular subtypes are creating clearer commercial winners. - Chemotherapy still leads on value, but growth is shifting to targeted drugs and outpatient care settings. What’s next: - The report expects targeted therapy to be the fastest-growing treatment segment at 10.2% CAGR through 2035. - Intrahepatic bile duct cancer will likely remain the largest type segment because FGFR2 fusions and IDH1 mutations are concentrated there. - Oncology centers and specialty clinics are expected to gain share as more treatment moves to oral drugs and shorter infusion protocols. - North America is forecast to stay dominant, while Asia-Pacific is projected to be the fastest-growing region at 9.5% CAGR. - The report also projects that by 2030, about 40% of newly diagnosed advanced patients will receive genomic profiling followed by matched therapy. The bottom line: - Bile duct cancer is becoming a precision medicine market, and the biggest growth is now tied to molecular testing, targeted approvals and broader reimbursement rather than chemotherapy volume alone.